Customize your JAMA Network experience by selecting one or more topics from the list below.
A JAMA THEME ISSUE
Edited by Robert M. Golub, MD, and Phil B. Fontanarosa, MD, MBA
Bevacizumab-carboplatin-paclitaxel has been an approved treatment regimen for advanced non–small cell lung cancer since 2006. In a retrospective cohort study of 4168 Medicare beneficiaries with advanced non–small cell lung cancer, Zhu and colleagues found that the addition of bevacizumab to carboplatin-paclitaxel therapy was not associated with improved survival.
In an analysis of data from 223 475 adults with major trauma admitted to level I or level II trauma centers, Galvagno and colleagues found that survival to hospital discharge was improved among patients transported by helicopter emergency medical services (EMS) compared with ground EMS transport.
This Week in JAMA. JAMA. 2012;307(15):1555. doi:10.1001/jama.2012.470
Create a personal account or sign in to: